Humoral response to influenza vaccination in relation to pre-vaccination antibody titres, vaccination history, cytomegalovirus serostatus and CD4/CD8 ratio

Infectious Diseases

Volumn 48, Issue 6, 2016, Pages 436-442

  Strindhall, Jan ^a   Ernerudh, Jan ^b   Mörner, Andreas ^c   Waalen, Kristian ^d   Löfgren, Sture ^e   Matussek, Andreas ^e   Bengner, Malin ^e  

^a JÖNKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^e RYHOV COUNTY HOSPITAL   (Sweden)

Author keywords

Cytomegalovirus; Immunosenescence; Influenza vaccination

Indexed keywords

ANTIBODY; HEMAGGLUTININ; INFLUENZA VACCINE; IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS ANTIGEN;

AGED; ANTIBODY TITER; ARTICLE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC PATIENT; CYTOMEGALOVIRUS; DRUG RESPONSE; FEMALE; HUMAN; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RISK; BLOOD; FLOW CYTOMETRY; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; IMMUNOSENESCENCE; INFLUENZA B VIRUS; PROCEDURES; VIROLOGY;

AGED; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; FLOW CYTOMETRY; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; IMMUNOSENESCENCE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE;

EID: 84968616764     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.3109/23744235.2015.1135252     Document Type: Article

References (47)

1. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24:1159-169.
2. Goronzy JJ, Fulbright JW, Crowson CS, et al. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol. 2001;75:12182-12187.
3. Mahnke YD, Saqr A, Hazenfeld S, et al. Age-related changes in durability and function of vaccine-elicited influenza-specific CD4(+) T-cell responses. Vaccine. 2011;29:8606-8614.
4. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med. 1995;123:518-527.
5. Saurwein-Teissl M, Lung TL, Marx F, et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28() T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol. 2002;168:5893-5899.
6. Xie D, McElhaney JE. Lower GrB + CD62Lhigh CD8 TCM effector lymphocyte response to influenza virus in older adults is associated with increased CD28null CD8 T lymphocytes. Mech Ageing Dev. 2007;128:392-400.
7. Grubeck-Loebenstein B, Della Bella S, Iorio AM, et al. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res. 2009;21:201-209.
8. Koch S, Larbi A, Ozcelik D, et al. Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci. 2007;1114:23-35.
9. Olsson J, Wikby A, Johansson B, et al. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev. 2000;121:187-201.
10. Pawelec G, Derhovanessian E, Larbi A, et al. Cytomegalovirus and human immunosenescence. Rev Med Virol. 2009;19:47-56
11. Wikby A, Johansson B, Olsson J, et al. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol. 2002;37:445-453.
12. Pawelec G. Immunosenenescence: role of cytomegalovirus. Exp Gerontol. 2014;54C:1-5.
13. Turner JE, Campbell JP, Edwards KM, et al. Rudimentary signs of immunosenescence in Cytomegalovirus-seropositive healthy young adults. Age (Dordr). 2014;36:287-297.
14. Wald A, Selke S, Magaret A, Boeckh M. Impact of human cytomegalovirus (CMV) infection on immune response to pandemic 2009 H1N1 influenza vaccine in healthy adults. J Med Virol. 2013;85:1557-1560.
15. Derhovanessian E, Theeten H, Hahnel K, et al. Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine. 2013;31:685-690.
16. Trzonkowski P, Mysliwska J, Szmit E, et al. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination-an impact of immunosenescence. Vaccine. 2003;21: 3826-3836.
17. den Elzen WP, Vossen AC, Cools HJ, et al. Cytomegalovirus infection and responsiveness to influenza vaccination in elderly residents of long-term care facilities. Vaccine. 2011;29:4869-4874.
18. Furman D, Jojic V, Sharma S, et al. Cytomegalovirus infection enhances the immune response to influenza. Sci Trans Med. 2015;7:281ra43.
19. Derhovanessian E, Maier AB, Hahnel K, et al. Latent infection with cytomegalovirus is associated with poor memory CD4 responses to influenza A core proteins in the elderly. J Immunol. 2014;193:3624-3631.
20. Gaglani M, Spencer S, Ball S, et al. Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine. J Infect Dis. 2014;209:1705-1714.
21. Kunzel W, Glathe H, Engelmann H, Van Hoecke C. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine. 1996;14:1108-1110.
22. Beyer WE, de Bruijn IA, Palache AM, et al. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med. 1999;159:182-188.
23. de Bruijn IA, Remarque EJ, Beyer WE, et al. Annually repeated influenza vaccination improves humoral responses to several influenza virus strains in healthy elderly. Vaccine. 1997;15:1323-1329
24. Hoskins TW, Davies JR, Smith AJ, et al. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ’s Hospital. Lancet. 1979;1:33-35.
25. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014;58:319-327.
26. Ahmed AE, Nicholson KG, Nguyen-Van-Tam JS. Reduction in mortality associated with influenza vaccine during 1989-90 epidemic. Lancet. 1995;346:591-595.
27. Keitel WA, Cate TR, Couch RB, et al. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine. 1997;15:1114-1122.
28. Voordouw AC, Sturkenboom MC, Dieleman JP, et al. Annual revaccination against influenza and mortality risk in community- dwelling elderly persons. JAMA. 2004;292:2089-2095
29. Wikby A, Maxson P, Olsson J, et al. Changes in CD8 and CD4 lymphocyte subsets, T cell proliferation responses and non-survival in the very old: the Swedish longitudinal OCTO-immune study. Mech Ageing Dev. 1998;102:187-198.
30. Ferguson FG, Wikby A, Maxson P, et al. Immune parameters in a longitudinal study of a very old population of Swedish people: a comparison between survivors and nonsurvivors. J Gerontol A Biol Sci Med Sci. 1995;50:B378-B382.
31. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull. 1979;35:69-75.
32. Couch RB, Kasel JA. Immunity to influenza in man. Ann Rev Microbiol. 1983;37:529-549.
33. Strindhall J, Skog M, Ernerudh J, et al. The inverted CD4/CD8 ratio and associated parameters in 66-year-old individuals: the Swedish HEXA immune study. Age (Dordr). 2013;35:985-991.
34. Waalen K, Kilander A, Dudman SG, et al. High prevalence of antibodies to the 2009 pandemic influenza A(H1N1) virus in the Norwegian population following a major epidemic and a large vaccination campaign in autumn 2009. Euro Surveill. 2010;15.
35. Davenport FM, Hennessy AV, Francis T Jr. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med. 1953;98:641-656.
36. Kim JH, Skountzou I, Compans R, Jacob J. Original antigenic sin responses to influenza viruses. J Immunol. 2009;183:3294-3301
37. Sun J, Braciale TJ. Role of T cell immunity in recovery from influenza virus infection. Curr Opin Virol. 2013;3:425-429.
38. Govaert TM, Sprenger MJ, Dinant GJ, et al. Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine. 1994;12:1185-1189.
39. Muszkat M, Friedman G, Dannenberg HD, et al. Response to influenza vaccination in community and in nursing home residing elderly: relation to clinical factors. Exp Gerontol. 2003;38:1199-1203
40. Sasaki S, He XS, Holmes TH, et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One. 2008;3:e2975.
41. Iorio AM, Camilloni B, Basileo M, et al. Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers. Gerontology. 2007;53:411-418.
42. Burns VE, Gallagher S. Antibody response to vaccination as a marker of in vivo immune function in psychophysiological research. Neurosci Biobehav Rev. 2010;35:122-126.
43. Edwards KM, Campbell JP, Ring C, et al. Exercise intensity does not influence the efficacy of eccentric exercise as a behavioural adjuvant to vaccination. Brain Behav Immun. 2010;24:623-630.
44. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci U S A. 1999;96:14001-14006.
45. Beyer WE, Palache AM, Sprenger MJ, et al. Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine. 1996;14:1331-1339.
46. Nabeshima S, Kashiwagi K, Murata M, et al. Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years. J Med Virol. 2007;79:320-325.
47. Wagar LE, Gentleman B, Pircher H, et al. Influenza-specific T cells from older people are enriched in the late effector subset and their presence inversely correlates with vaccine response. PLoS One. 2011;6:e23698